| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | lapatinib | CCLE | pan-cancer | AAC | 0.18 | 0.0002 |
| mRNA | TKI258 | CCLE | pan-cancer | AAC | -0.16 | 0.002 |
| mRNA | Erlotinib | CCLE | pan-cancer | AAC | 0.15 | 0.002 |
| mRNA | AZD0530 | CCLE | pan-cancer | AAC | 0.12 | 0.02 |
| mRNA | Sorafenib | CCLE | pan-cancer | AAC | -0.11 | 0.03 |
| mRNA | Crizotinib | CCLE | pan-cancer | AAC | -0.1 | 0.05 |
| mRNA | PLX4720 | CCLE | pan-cancer | AAC | -0.096 | 0.05 |
| mRNA | 17-AAG | CCLE | pan-cancer | AAC | -0.1 | 0.05 |
| mRNA | Vandetanib | CCLE | pan-cancer | AAC | 0.099 | 0.06 |
| mRNA | PD-0332991 | CCLE | pan-cancer | AAC | -0.1 | 0.06 |